Aldeyra Therapeutics Class Action Lawsuit – ALDX

Introduction

A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and certain of its senior officers on behalf of investors who purchased or acquired Aldeyra securities between November 3, 2023 and March 16, 2026. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the clinical trial results for reproxalap, the company's lead drug candidate for the treatment of dry eye disease. According to the lawsuit, defendants repeatedly touted reproxalap's "broad-based, rapid-onset activity" and "consistent" clinical results while concealing that the trial results were, in fact, inconsistent and that any positive findings were unreliable and not meaningful. When the U.S. Food and Drug Administration issued a Complete Response Letter on March 17, 2026, rejecting the drug's application and citing a "lack of substantial evidence" of efficacy, Aldeyra's stock price collapsed by approximately 70.7%, closing at $1.24 per share.

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. The company's lead product candidate, reproxalap, is a novel reactive aldehyde species (RASP) inhibitor that was under investigation as a treatment for dry eye disease.

Class Period

November 3, 2023 – March 16, 2026, inclusive.

Investors who purchased or acquired Aldeyra Therapeutics (ALDX) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that Aldeyra Therapeutics and its senior officers, CEO Todd C. Brady, Head of Finance Michael Alferi, and former interim CFO Bruce M. Greenberg, made a series of materially false and misleading statements about the clinical trial performance of reproxalap, the company's flagship drug candidate. In SEC filings spanning the entire Class Period, defendants consistently represented that reproxalap had "demonstrated broad-based, rapid-onset activity and consistent safety across a number of Phase 2 and Phase 3 clinical trials" and that it had shown "consistent statistically significant and clinically relevant activity across a variety of symptoms and signs, occurring as early as within minutes of dosing."

These representations appeared in the company's quarterly report for the third quarter of 2023, filed November 3, 2023, and were signed by Brady and Greenberg. Substantially identical language was repeated in the annual reports for fiscal years 2023, 2024, and 2025, filed on March 7, 2024, February 28, 2025, and February 27, 2026, respectively. The fiscal year 2023 report was signed by Brady and Greenberg, while the fiscal year 2024 and 2025 reports were signed by Brady and Alferi, who assumed the principal financial officer role on August 31, 2024.

According to the complaint, these statements were materially false and misleading because the clinical trial results for reproxalap were not consistent across studies. The complaint alleges that this inconsistency rendered the positive findings defendants highlighted unreliable and not meaningful, a reality defendants knew or recklessly disregarded. By repeatedly characterizing reproxalap's trial data as demonstrating consistent efficacy, defendants allegedly concealed the fundamental weakness in the clinical evidence supporting the drug's viability, artificially inflating the price of Aldeyra securities throughout the Class Period.

The Truth Emerges

On March 17, 2026, before the market opened, Aldeyra disclosed in a Form 8-K filing that the company had received a Complete Response Letter from the FDA, a formal rejection of its drug application. The Complete Response Letter was devastating in its assessment: the FDA stated there was "a lack of substantial evidence" that reproxalap "will have the effect it purports or is represented to have" and that "the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease."

Critically, the FDA's letter directly contradicted the core of defendants' years-long representations to investors. The agency stated that "the inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings" and that "the totality of evidence from the completed clinical trials does not support the effectiveness of the product." The complaint alleges that FDA's characterization of the trial results as inconsistent confirmed that the confident language about consistent activity in the company's SEC filings had been materially misleading.

Market Reaction

The market's response to the FDA's Complete Response Letter was swift and severe. On March 17, 2026, ALDX shares plummeted $2.99, or approximately 70.7%, to close at just $1.24 per share. The magnitude of the decline reflects the degree to which the market had relied on defendants' repeated assurances about the consistency and significance of reproxalap's clinical data, assurances that the FDA's letter revealed to be materially misleading.

Next Steps

●              The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●              The Court will then consider motion for class certification.

●              The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Check Eligibility